Ipsen doles out €52M to upgrade its Dublin manufacturing site, increase capacity

Aiming to boost its presence in Ireland, Ipsen has spent 52 million euros to upgrade its Dublin manufacturing site.

The expanded site in Blanchardstown will allow Ipsen to boost its production of active pharmaceutical ingredients by 10% this year compared with 2021. The company plans to invest 15 million euros more in the site between 2023 and 2026 as part of its growth strategy for the Irish market.

Ipsen employs 175 workers at the site, a number that has increased by 20% since 2019.

Ireland “plays an important role as part of Ipsen’s international network,” Ipsen CEO David Loew said in a statement. “This new investment in Dublin is a milestone in our ongoing journey of innovation and our growing footprint in Ireland.”

Loew, a former Sanofi executive, joined Ipsen as CEO back in 2020.

The Irish expansion comes amid a busy year for Ipsen. In June, the company revealed its agreement to acquire oncology specialist Epizyme for $247 million, bringing Epizyme’s Tazverik, a chemotherapy free EZH2a inhibitor, under its belt.

That move came after the company unveiled its plan to split off its consumer healthcare business. With the split, Ipsen aims to create a leaner company focused on specialty care.